These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36856175)

  • 1. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
    Shi X; Li S; Tang S; Lu Y
    Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib inhibits the proliferation and induces apoptosis by inactivating the AKT pathway in androgen receptor-negative prostate cancer cells.
    Xu Y; Zheng J; Ye ZY
    Neoplasma; 2022 Sep; 69(5):1119-1128. PubMed ID: 36004650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on the mechanism of androsta-4,6,8,14-tetraene-3,11,16-trione against acute lymphoblastic leukemia.
    Chen D; Wang Y; Xiao S; Cheng G; Liu Y; Zhao T; Cao J; Wen Y
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106573. PubMed ID: 38909867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
    Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
    Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Paeoniflorin induces apoptosis and cycle arrest in B-cell acute lymphoblastic leukemia cells by inhibiting SENP1/c-Myc signaling pathway].
    Qin X; Chen X; Liu J; Zeng Y; Guo L; Liu WJ
    Zhongguo Zhong Yao Za Zhi; 2022 Jun; 47(12):3312-3319. PubMed ID: 35851125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
    Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
    Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.
    Dida F; Li Y; Iwao A; Deguchi T; Azuma E; Komada Y
    Exp Hematol; 2008 Oct; 36(10):1343-53. PubMed ID: 18599181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role and mechanism of AZD5363 anti-leukemia activity in T-cell acute lymphoblastic leukemia.
    Luo D; Li S; Guo J; Yue H; Shi L; Liu R; Wang J; Shi X
    Eur J Pharmacol; 2024 Jan; 963():176268. PubMed ID: 38096965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanism of napabucasin, a naturally derived furanonaphthoquinone: apoptosis and autophagy induction in lung cancer cells through direct targeting on Akt/mTOR proteins.
    Petsri K; Thongsom S; Racha S; Chamni S; Jindapol S; Kaekratoke N; Zou H; Chanvorachote P
    BMC Complement Med Ther; 2022 Sep; 22(1):250. PubMed ID: 36180880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
    Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
    Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
    Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
    Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.
    Song X; Rao H; Guo C; Yang B; Ren Y; Wang M; Li Y; Cao Z; Pei J
    Phytomedicine; 2021 Dec; 93():153802. PubMed ID: 34710755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
    Ehm P; Grottke A; Bettin B; Jücker M
    Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis.
    Jin X; Jiao X; Jiao J; Zhang T; Cui B
    Gene; 2018 Aug; 669():99-106. PubMed ID: 29800735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
    Jiang M; Zou X; Lu L
    Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways.
    Zhang XJ; Jia SS
    Biomed Pharmacother; 2016 Oct; 83():1164-1174. PubMed ID: 27551764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.